Variable | All patients (n = 26) | Sensitive (n = 18) | Primary resistant (n = 8) |
---|---|---|---|
Age (years), median (range) | 60 (20–80) | 61 (40–79) | 58 (20–80) |
Sex, n (%) | |||
 Female | 11 (42) | 8 (44) | 3 (38) |
 Male | 15 (58) | 10 (56) | 5 (62) |
Histology, n (%) | |||
 Clear cell carcinoma | 17 (65) | 13 (72) | 4 (50) |
 Papillary carcinoma | 3 (12) | 1 (6) | 2 (25) |
 Mixed type1 | 6 (23) | 4 (22) | 2 (25) |
Prior systemic therapy, n (%) | |||
 0 | 17 (65) | 10 (55) | 7 (88) |
 1 | 8 (31) | 7 (39) | 1 (12) |
 2 | 1 (4) | 1 (6) | – |
PFS (months), median (range) |  | 8.8 (5–62.3) | 2.3 (1.5–2.8) |
Time to sunitinib (months), median (range) | 6 (1–63) | 6 (1–63) | 6 (1–24) |